Arcutis Biotherapeutics (ARQT) News Today $12.68 -1.07 (-7.78%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 9.3%Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) saw a significant drop in short interest in December. As of December 31st, there was short interest totalling 20,970,000 shares, a drop of 9.3% from the December 15th total of 23,110,000 shares. Based on an average daily trading volume, of 2,050,000 shares, the days-to-cover ratio is presently 10.2 days.January 17 at 6:30 PM | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4% - Here's WhyArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4% - Time to Sell?January 17 at 3:06 PM | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from HC WainwrightJanuary 15 at 3:27 AM | americanbankingnews.comArcutis Biotherapeutics’ Robust Revenue Growth and Strategic Financial Positioning Underpin Buy RatingJanuary 14, 2025 | markets.businessinsider.comTD Cowen Remains a Buy on Arcutis Biotherapeutics (ARQT)January 13, 2025 | markets.businessinsider.comArcutis Biotherapeutics price target raised to $20 from $18 at NeedhamJanuary 13, 2025 | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up - Still a Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up - Still a Buy?January 13, 2025 | marketbeat.comArcutis Shares Climb on Strong Product Revenue EstimatesJanuary 13, 2025 | marketwatch.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Hologic (HOLX) and Arcutis Biotherapeutics (ARQT)January 13, 2025 | markets.businessinsider.comStrong Financial Performance and Growth Prospects Drive Buy Rating for Arcutis BiotherapeuticsJanuary 13, 2025 | markets.businessinsider.comDemystifying Arcutis Biotherapeutics: Insights From 5 Analyst ReviewsJanuary 13, 2025 | benzinga.comHC Wainwright Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT)HC Wainwright reaffirmed a "buy" rating and issued a $19.00 target price on shares of Arcutis Biotherapeutics in a report on Monday.January 13, 2025 | marketbeat.comArcutis Biotherapeutics reports preliminary Q4 revenue $63M, consensus $54.95MJanuary 12, 2025 | markets.businessinsider.comArcutis Biotherapeutics Projects Surge In Q4 Revenue GrowthJanuary 12, 2025 | markets.businessinsider.comArcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 MillionJanuary 12, 2025 | globenewswire.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.5% - Here's What HappenedArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 8.5% - Here's What HappenedJanuary 10, 2025 | marketbeat.comArcutis Biotherapeutics price target raised to $20 from $19 at MizuhoJanuary 8, 2025 | markets.businessinsider.comMizuho Forecasts Strong Price Appreciation for Arcutis Biotherapeutics (NASDAQ:ARQT) StockMizuho increased their target price on shares of Arcutis Biotherapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday.January 7, 2025 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week High - What's Next?Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 1-Year High - Time to Buy?January 7, 2025 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus Sells 10,000 SharesJanuary 7, 2025 | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard G. Welgus sold 10,000 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $14.67, for a total value of $146,700.00. Following the completion of the sale, the director now directly owns 151,944 shares in the company, valued at approximately $2,229,018.48. The trade was a 6.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 6, 2025 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7% - Time to Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 7% - What's Next?January 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for ARQT FY2024 Earnings?Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Investment analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Arcutis Biotherapeutics in a research report issued to clients and investors on Monday, December 30th. HC Wainwright analyst D. TsaJanuary 1, 2025 | marketbeat.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 1,691 Shares of StockJanuary 1, 2025 | insidertrades.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Patrick Burnett Sells 1,691 SharesArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Patrick Burnett sold 1,691 shares of the company's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $14.00, for a total value of $23,674.00. Following the transaction, the insider now owns 126,978 shares of the company's stock, valued at approximately $1,777,692. The trade was a 1.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.December 31, 2024 | marketbeat.comArcutis Biotherapeutics initiated with a Buy at H.C. WainwrightDecember 31, 2024 | markets.businessinsider.comAmerican Air upgraded, Nordstrom downgraded: Wall Street's top analyst callsDecember 30, 2024 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy RecommendationDecember 30, 2024 | msn.comArcutis Biotherapeutics (NASDAQ:ARQT) Coverage Initiated by Analysts at HC WainwrightHC Wainwright initiated coverage on Arcutis Biotherapeutics in a research note on Monday. They issued a "buy" rating and a $19.00 price target for the company.December 30, 2024 | marketbeat.comGeode Capital Management LLC Has $22.98 Million Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Geode Capital Management LLC boosted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 2.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,470,138 shares of the company's stock after purchasingDecember 28, 2024 | marketbeat.comBarclays PLC Raises Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Barclays PLC grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 45.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 253,392 shares of the company's stockDecember 26, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $227,550.00 in StockDecember 24, 2024 | insidertrades.comTodd Franklin Watanabe Sells 15,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Todd Franklin Watanabe sold 15,000 shares of Arcutis Biotherapeutics stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $15.17, for a total transaction of $227,550.00. Following the completion of the sale, the insider now owns 823,430 shares in the company, valued at approximately $12,491,433.10. This trade represents a 1.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.December 23, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.2% - Time to Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.2% Higher - Still a Buy?December 20, 2024 | marketbeat.comState Street Corp Boosts Stock Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)State Street Corp raised its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 9.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,641,631 shares of the company's stock after purchDecember 20, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 9.4% - What's Next?Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 9.4% - What's Next?December 18, 2024 | marketbeat.comArcutis Biotherapeutics Soars on Zoryve Success and Bullish Analyst RatingsDecember 18, 2024 | msn.comFranklin Resources Inc. Decreases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Franklin Resources Inc. decreased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,250,418 shares of the company's sDecember 18, 2024 | marketbeat.comArcutis Biotherapeutics submits sNDA for ZORYVE cream to FDADecember 17, 2024 | markets.businessinsider.comTraders Buy High Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock traders purchased 21,719 call options on the company. This represents an increase of approximately 1,193% compared to the typical volume of 1,680 call options.December 17, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week High - Here's WhyArcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 12-Month High - Here's WhyDecember 16, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Drop in Short InterestArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 23,530,000 shares, a decrease of 6.0% from the November 15th total of 25,020,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is currently 11.8 days.December 16, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)December 16, 2024 | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.8% - Still a Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.8% Higher - Still a Buy?December 13, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New $2.27 Million Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Point72 Asset Management L.P. acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 244,386 shares of the company's stock, valued at approDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 75,737 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Jacobs Levy Equity Management Inc. reduced its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 43.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 100,172 shares of the company's stock after selDecember 9, 2024 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comHoward G. Welgus Sells 10,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockDecember 4, 2024 | insidertrades.comShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Drops By 9.9%Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 25,020,000 shares, a decline of 9.9% from the October 31st total of 27,760,000 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is currently 12.8 days.December 1, 2024 | marketbeat.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.500.72▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼176▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BBIO News Today LEGN News Today ELAN News Today CYTK News Today NUVL News Today GRFS News Today VKTX News Today TGTX News Today AXSM News Today KRYS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARQT Stock Alerts